Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly alvocidib in previously treated CLL or PLL arising from CLL
2006-006152-34Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alvocidib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and prolymphocytic leukemia (PLL), sponsored by Sanofi. Primary endpoint: Overall objective response rate. Started Apr 2007; status: completed.
02
Drugs
alvocidib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on 2006-006152-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006152-34.